Kuongorora Mushonga Mutsva Wemushonga Wechisingaperi Hepatitis B

rakanyorwa mupepeti

Kune vangangosvika miriyoni 1.59 yevarwere vane hepatitis B (CHB) muUS Ascletis Pharma Inc. yazivisa nhasi kubvumidzwa kwechirongwa cheInvestigational New Drug (IND) neUS Food and Drug Administration (FDA) uye kutangwa kwebudiriro yepasi rose yeASC22 (Envafolimab) , yekutanga-mu-kirasi, inoiswa pasi peganda PD-L1 antibody yekushanda kwekurapa kwechisingaperi hepatitis B (CHB).

Print Friendly, PDF & Email

Bepa retsvagiridzo razvino [1], rakanzi "Kuwanda kweChirwere cheHepatitis B Hutachiona muUnited States" rakaburitswa muna Chikumi 2020, rakaratidza huwandu hunofungidzirwa hwehutachiona hwehutachiona hweH hepatitis B (HBV) muUS yevarwere vane miriyoni 1.59 (kusiyana. 1.25–2.49 miriyoni). Vese World Health Organisation (WHO) neUS Department of Health and Human Services (DHHS) vakatsanangura zvirongwa zvekupedza hepatitis.

ASC22 Phase IIb yekudzidza (ClinicalTrials.gov Identifier: NCT04465890) ndeye randomized, single-bofu, placebo-inodzorwa, multi-center kiriniki yekuedza muChina iyo inoongorora kushanda uye kuchengetedzeka kwevarwere ve149 CHB kwemavhiki makumi maviri nemana kurapwa kwe24 mg/ kg kana 1 mg/kg ASC2.5 kana kuenzanisa placebo kunopiwa kamwe chete mavhiki maviri ega ega (Q22W) pamwe chete neNAs. Mhedzisiro yenguva pfupi, iyo yakagamuchirwa yehurukuro yemuromo muLate Breaking Session paThe Liver Meeting® 2 neAmerican Association for the Study of Liver Diseases (AASLD) yakaratidza kuti muvarwere vane baseline hepatitis B surface antigen (HBsAg) level ≤ 2021 IU. /mL, ingangoita 500% (19/3) yevarwere vari muboka rekurapa vakawana kurasikirwa kweHBsAg maringe pasina chidzidzo chakawana kurasikirwa kweHBsAg muboka re placebo uye hapana rebound mushure mekupedzisira dosing yeASC16, ichiratidza HBV inoshanda kurapwa.

Phase IIa uye IIb zvidzidzo zvekiriniki zveASC22 yeHBV inoshanda kurapwa yakasarudzwa kuti ibatanidzwe mu "Yakanakisa yeThe Liver Meeting's Summary" muna 2021 neAASLD komiti yekuongorora. Kusanganisirwa kwakadaro rukudzo rweumwe uye kunoratidza mwero wepamusoro uyo komiti yekuongorora yeAASLD inotarisa tsvagiridzo yeAscletis muCHB inoshanda kurapwa.

Ascletis yakazivisa kuti yakanga yawana rezinesi repasi rose uye rakasarudzika kubva ku8 Mbudzi, 2021 kubva kuSuzhou Alphamab yekugadzira nekutengesa ASC22 yezvirwere zvese zvehutachiona zvinosanganisira Hepatitis B. Ascletis mabhuku anotengesa pasi rose reASC22 yezvirwere zvese nemavhairasi.

ASC22 ndiyo yakanyanyisa kiriniki nhanho immunotherapy munyika yeCHB inoshanda kurapa, kureva kurasikirwa kweHBsAg, kuburikidza nekuvharira PD-1/PD-L1 nzira.

Print Friendly, PDF & Email

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Leave a Comment

2 Comments

  • Mhedzisiro yangu yehepatitis B yakachinja mushure mekushandisa Herbal Garden HBV mishonga yemakwenzi kweMASVONDO MATANHU. Ndakapedzisira kuedza 2021 uye ndakanga ndichiri negative. Zvese nekuda kweHerbal Garden. Unogona kubata navo kuburikidza herbalgarden4@gmail.com kune chero kurapwa kwechirwere chisingaperi